Sartorius Stedim Biotech Announces Share and Voting Rights Update

Sartorius Stedim Biotech SA has released a statement regarding the composition of its issued capital as of October 31, 2025. The company, based in Aubagne, France, specified the total number of shares and voting rights. The issued capital consists of 97,330,405 shares. The total theoretical voting rights, which include treasury shares, amount to 165,543,716. Excluding treasury shares, the net voting rights tally up to 165,512,326.

This update is in accordance with Article L 233-8-II of the French Code of Commerce and Article 223-6 of the General Regulations of the AMF. The regulatory filing emphasized transparency and adherence to financial reporting standards. This announcement was disseminated by EQS Group, underscoring Sartorius Stedim Biotech's commitment to regulatory compliance.